A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation - American College of Cardiolog

Some good news for those on NOAC. New drug - Clinical trials were stopped early because of good outcomes. Not sure when it will be ready for patients.

[www.acc.org]

Press Release: Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation.

Yes, potentially very good news. They definitely proved that bleeding risk is significantly reduced vs NOAC's, but they still have to prove that stroke risk will be acceptable vs current NOAC's. That would be another trial, so probably a bit of a wait.

Jim